AstraZeneca Organizational Structure & Org Chart

AstraZeneca organizational chart

Edit this organizational chart

AstraZeneca's reporting structure as of 2026-09. Drag to pan, scroll to zoom — or open it in QueryChart and edit it as your own.

About the company

AstraZeneca is a biopharmaceuticals organization. Its current public materials identify Oncology, BioPharmaceuticals, Rare Disease as useful ways to understand its activities. AstraZeneca publicly emphasizes Oncology, BioPharmaceuticals and Rare Disease; Rare Disease includes the Alexion business. The chart uses these published therapy platforms rather than unsupported internal reporting lines.

This QueryChart tree puts those disclosed areas next to a single, separately marked leadership branch for Pascal Soriot. The business branches describe a public portfolio, not a confidential employee hierarchy. A line between a category and an offering means the offering belongs in that published category; it does not say that a particular executive personally manages every team shown.

Published businesses and operating areas

Oncology is one of the visible areas in AstraZeneca's published structure. Cancer research and medicines form a major global therapy portfolio. The editable chart places Cancer medicines and Oncology research beneath this branch so a reader can find concrete activities instead of a generic departmental box. This is a simplified grouping of disclosed work, and the sources below should be used for the exact legal entities, segment definitions and current management roles.

BioPharmaceuticals is one of the visible areas in AstraZeneca's published structure. This portfolio spans cardiovascular, renal, metabolic, respiratory and immune-related diseases. The editable chart places CVRM and Respiratory and Immunology beneath this branch so a reader can find concrete activities instead of a generic departmental box. This is a simplified grouping of disclosed work, and the sources below should be used for the exact legal entities, segment definitions and current management roles.

Rare Disease is one of the visible areas in AstraZeneca's published structure. Alexion provides a rare-disease platform within AstraZeneca. The editable chart places Alexion medicines and Rare-disease research beneath this branch so a reader can find concrete activities instead of a generic departmental box. This is a simplified grouping of disclosed work, and the sources below should be used for the exact legal entities, segment definitions and current management roles.

Key leadership roles

1. Pascal Soriot

   Chief executive officer

How this structure supports the business

The Oncology and BioPharmaceuticals branches answer different questions about AstraZeneca. Cancer research and medicines form a major global therapy portfolio. This portfolio spans cardiovascular, renal, metabolic, respiratory and immune-related diseases. Showing them side by side is more informative than drawing an unsupported chain of managers, particularly when the public materials report a portfolio or service line rather than a complete internal org chart.

AstraZeneca publicly emphasizes Oncology, BioPharmaceuticals and Rare Disease; Rare Disease includes the Alexion business. The chart uses these published therapy platforms rather than unsupported internal reporting lines. Alexion provides a rare-disease platform within AstraZeneca. The diagram makes that distinguishing feature visible while keeping the named leadership layer separate. It is useful as a starting point for an editable company chart; users can replace the public groupings with their own teams, roles and verified reporting relationships.

Advantages and disadvantages

The Oncology branch uses a publicly described company-specific grouping.

A portfolio branch does not prove an individual reporting line.

The chart distinguishes BioPharmaceuticals from Rare Disease.

A single-parent tree cannot show every cross-business collaboration or legal-entity link.

Interesting facts

• AstraZeneca's public materials identify Oncology as a major area.
• BioPharmaceuticals includes CVRM and Respiratory and Immunology in this educational map.
• Rare Disease is shown separately because alexion provides a rare-disease platform within AstraZeneca.
• The principal leadership role is identified as Pascal Soriot.

Related process templates

• Batch release process flowchart (QP certification to despatch)
• Equipment calibration process flowchart (as-found to return to service)

Related organization charts

• Pfizer Organizational Structure & Org Chart
• Novartis Organizational Structure & Org Chart
• Eli Lilly Organizational Structure & Org Chart
• Novo Nordisk Organizational Structure
• Johnson & Johnson Organizational Structure & Org Chart
• Roche Organizational Structure & Org Chart

Frequently asked questions

How is AstraZeneca organized?

This educational chart maps Oncology, BioPharmaceuticals, Rare Disease, using the company's public materials. It does not attempt to reproduce a full internal employee hierarchy.

Who leads AstraZeneca?

Pascal Soriot is the publicly identified chief executive officer in the sources reviewed on 29 September 2026.

Is this an official AstraZeneca org chart?

No. It is an independent reconstruction of public business categories and leadership information, with simplified connections for exploration and editing.

Use this org chart template

Open this AstraZeneca structure in QueryChart and rename roles, add departments, remove areas or change connections for your own organization.

Edit this organizational chart